Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,078
archived clinical trials in
Major Depression Disorder (MDD)

Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  8/20/2012
Forest Investigative Site 009
mi
from
Orange, CA
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 8/20/2012
Forest Investigative Site 009
mi
from
Orange, CA
Click here to add this to my saved trials
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  8/20/2012
Forest Investigative Site 005
mi
from
Riverside, CA
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 8/20/2012
Forest Investigative Site 005
mi
from
Riverside, CA
Click here to add this to my saved trials
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  8/20/2012
Forest Investigative Site 010
mi
from
Costa Mesa, CA
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 8/20/2012
Forest Investigative Site 010
mi
from
Costa Mesa, CA
Click here to add this to my saved trials
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  8/20/2012
Forest Investigative site 005
mi
from
Pembroke Pines, FL
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 8/20/2012
Forest Investigative site 005
mi
from
Pembroke Pines, FL
Click here to add this to my saved trials
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  8/20/2012
Forest Investigative site 004
mi
from
Tampa, FL
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 8/20/2012
Forest Investigative site 004
mi
from
Tampa, FL
Click here to add this to my saved trials
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  8/20/2012
Forest Investigative Site
mi
from
Atlanta, GA
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 8/20/2012
Forest Investigative Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  8/20/2012
Forest Investigative Site 001
mi
from
Towson, MD
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 8/20/2012
Forest Investigative Site 001
mi
from
Towson, MD
Click here to add this to my saved trials
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  8/20/2012
Forest Investigative Site
mi
from
Cleveland, OH
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 8/20/2012
Forest Investigative Site
mi
from
Cleveland, OH
Click here to add this to my saved trials
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  8/20/2012
Forest Investigative site 011
mi
from
Broomall, PA
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 8/20/2012
Forest Investigative site 011
mi
from
Broomall, PA
Click here to add this to my saved trials
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  8/20/2012
Forest Investigative Site
mi
from
Lincoln, RI
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 8/20/2012
Forest Investigative Site
mi
from
Lincoln, RI
Click here to add this to my saved trials
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  8/20/2012
Forest Investigative Site
mi
from
Memphis, TN
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 8/20/2012
Forest Investigative Site
mi
from
Memphis, TN
Click here to add this to my saved trials
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  8/20/2012
Forest Investigative Site
mi
from
Houston, TX
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 8/20/2012
Forest Investigative Site
mi
from
Houston, TX
Click here to add this to my saved trials
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  8/20/2012
Forest Investigative Site
mi
from
Bellevue, WA
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 8/20/2012
Forest Investigative Site
mi
from
Bellevue, WA
Click here to add this to my saved trials
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  8/20/2012
Forest Investigative Site #027
mi
from
Seattle, WA
Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 8/20/2012
Forest Investigative Site #027
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated:  8/30/2012
GSK Investigational Site
mi
from
Cerritos, CA
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated: 8/30/2012
GSK Investigational Site
mi
from
Cerritos, CA
Click here to add this to my saved trials
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated:  8/30/2012
GSK Investigational Site
mi
from
San Diego, CA
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated: 8/30/2012
GSK Investigational Site
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated:  8/30/2012
GSK Investigational Site
mi
from
Torrance, CA
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated: 8/30/2012
GSK Investigational Site
mi
from
Torrance, CA
Click here to add this to my saved trials
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated:  8/30/2012
GSK Investigational Site
mi
from
Jacksonville, FL
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated: 8/30/2012
GSK Investigational Site
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated:  8/30/2012
GSK Investigational Site
mi
from
Miami, FL
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated: 8/30/2012
GSK Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated:  8/30/2012
GSK Investigational Site
mi
from
Atlanta, GA
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated: 8/30/2012
GSK Investigational Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated:  8/30/2012
GSK Investigational Site
mi
from
Marietta, GA
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated: 8/30/2012
GSK Investigational Site
mi
from
Marietta, GA
Click here to add this to my saved trials
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated:  8/30/2012
GSK Investigational Site
mi
from
Chicago, IL
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated: 8/30/2012
GSK Investigational Site
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated:  8/30/2012
GSK Investigational Site
mi
from
Skokie, IL
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated: 8/30/2012
GSK Investigational Site
mi
from
Skokie, IL
Click here to add this to my saved trials
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated:  8/30/2012
GSK Investigational Site
mi
from
Shreveport, LA
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated: 8/30/2012
GSK Investigational Site
mi
from
Shreveport, LA
Click here to add this to my saved trials
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated:  8/30/2012
GSK Investigational Site
mi
from
Rockville, MD
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated: 8/30/2012
GSK Investigational Site
mi
from
Rockville, MD
Click here to add this to my saved trials
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated:  8/30/2012
GSK Investigational Site
mi
from
Albuquerque, NM
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated: 8/30/2012
GSK Investigational Site
mi
from
Albuquerque, NM
Click here to add this to my saved trials
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated:  8/30/2012
GSK Investigational Site
mi
from
Raleigh, NC
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated: 8/30/2012
GSK Investigational Site
mi
from
Raleigh, NC
Click here to add this to my saved trials
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated:  8/30/2012
GSK Investigational Site
mi
from
Cincinnati, OH
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated: 8/30/2012
GSK Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated:  8/30/2012
GSK Investigational Site
mi
from
Philadelphia, PA
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated: 8/30/2012
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated:  8/30/2012
GSK Investigational Site
mi
from
Memphis, TN
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated: 8/30/2012
GSK Investigational Site
mi
from
Memphis, TN
Click here to add this to my saved trials
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated:  8/30/2012
GSK Investigational Site
mi
from
Brown Deer, WI
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated: 8/30/2012
GSK Investigational Site
mi
from
Brown Deer, WI
Click here to add this to my saved trials
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated:  8/30/2012
GSK Investigational Site
mi
from
Madison, WI
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder
Status: Enrolling
Updated: 8/30/2012
GSK Investigational Site
mi
from
Madison, WI
Click here to add this to my saved trials
Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression
Randomized, Double Blind, Placebo Controlled, Single IV Dose Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated:  9/10/2012
Mulitple
mi
from
Evanston, IL
Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression
Randomized, Double Blind, Placebo Controlled, Single IV Dose Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated: 9/10/2012
Mulitple
mi
from
Evanston, IL
Click here to add this to my saved trials
Depression Outcomes Study of Exercise
Adapting Exercise Treatment for Depression to Adolescents: A Pilot Study
Status: Enrolling
Updated:  9/14/2012
Klein Buendel, Inc
mi
from
Golden, CO
Depression Outcomes Study of Exercise
Adapting Exercise Treatment for Depression to Adolescents: A Pilot Study
Status: Enrolling
Updated: 9/14/2012
Klein Buendel, Inc
mi
from
Golden, CO
Click here to add this to my saved trials
Stimulant Enhancement of Well-Being Therapy for Depression
Stimulant Enhancement of Well-Being Therapy for Depression
Status: Enrolling
Updated:  9/17/2012
Depression Clinical and Research Program
mi
from
Boston, MA
Stimulant Enhancement of Well-Being Therapy for Depression
Stimulant Enhancement of Well-Being Therapy for Depression
Status: Enrolling
Updated: 9/17/2012
Depression Clinical and Research Program
mi
from
Boston, MA
Click here to add this to my saved trials
Eszopiclone Co-Administered With Escitalopram for Insomnia in Elderly Adults With Major Depressive Disorder
Eszopiclone Co-Administered With Escitalopram for Insomnia in Elderly Adults With Major Depressive Disorder
Status: Enrolling
Updated:  10/2/2012
Lehigh Center for Clinical Research
mi
from
Allentown, PA
Eszopiclone Co-Administered With Escitalopram for Insomnia in Elderly Adults With Major Depressive Disorder
Eszopiclone Co-Administered With Escitalopram for Insomnia in Elderly Adults With Major Depressive Disorder
Status: Enrolling
Updated: 10/2/2012
Lehigh Center for Clinical Research
mi
from
Allentown, PA
Click here to add this to my saved trials
Pilot Study in Multi-Coil Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Depression
Determining Effectiveness of Multi-Coil rTMS for Patients With Major Depressive Disorder: A Pilot Study
Status: Enrolling
Updated:  10/4/2012
Emory University
mi
from
Atlanta, GA
Pilot Study in Multi-Coil Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Depression
Determining Effectiveness of Multi-Coil rTMS for Patients With Major Depressive Disorder: A Pilot Study
Status: Enrolling
Updated: 10/4/2012
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Pilot Study in Multi-Coil Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Depression
Determining Effectiveness of Multi-Coil rTMS for Patients With Major Depressive Disorder: A Pilot Study
Status: Enrolling
Updated:  10/4/2012
Rush Medical College
mi
from
Chicago, IL
Pilot Study in Multi-Coil Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Depression
Determining Effectiveness of Multi-Coil rTMS for Patients With Major Depressive Disorder: A Pilot Study
Status: Enrolling
Updated: 10/4/2012
Rush Medical College
mi
from
Chicago, IL
Click here to add this to my saved trials
Pilot Study in Multi-Coil Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Depression
Determining Effectiveness of Multi-Coil rTMS for Patients With Major Depressive Disorder: A Pilot Study
Status: Enrolling
Updated:  10/4/2012
Medical University of South Carolina
mi
from
Charleston, SC
Pilot Study in Multi-Coil Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Depression
Determining Effectiveness of Multi-Coil rTMS for Patients With Major Depressive Disorder: A Pilot Study
Status: Enrolling
Updated: 10/4/2012
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Cognitive-behavioral Therapy vs. Light Therapy for Preventing SAD Recurrence
Cognitive-behavioral Therapy vs. Light Therapy for Preventing Seasonal Affective Disorder Recurrence
Status: Enrolling
Updated:  10/22/2012
University of Vermont, Psychology Department
mi
from
Burlington, VT
Cognitive-behavioral Therapy vs. Light Therapy for Preventing SAD Recurrence
Cognitive-behavioral Therapy vs. Light Therapy for Preventing Seasonal Affective Disorder Recurrence
Status: Enrolling
Updated: 10/22/2012
University of Vermont, Psychology Department
mi
from
Burlington, VT
Click here to add this to my saved trials
Cognitive Deficits in Major Depressive Disorder and Bipolar Disorder, Depressed Type: Prevalence and Improvement With Treatment of Depressive Symptoms
Cognitive Deficits in Major Depressive Disorder and Bipolar Disorder Depressed Type: Prevalence and Symptoms With Treating of Depressive Symptoms
Status: Enrolling
Updated:  11/2/2012
Massachusetts General Hospital
mi
from
Boston, MA
Cognitive Deficits in Major Depressive Disorder and Bipolar Disorder, Depressed Type: Prevalence and Improvement With Treatment of Depressive Symptoms
Cognitive Deficits in Major Depressive Disorder and Bipolar Disorder Depressed Type: Prevalence and Symptoms With Treating of Depressive Symptoms
Status: Enrolling
Updated: 11/2/2012
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Cognitive Behavioral Treatments for Depression in Chronic Illness
Cognitive Behavioral Treatments for Depression in Patients With Chronic Illness
Status: Enrolling
Updated:  11/15/2012
Glendale Adventist Medical Center
mi
from
Glendale, CA
Cognitive Behavioral Treatments for Depression in Chronic Illness
Cognitive Behavioral Treatments for Depression in Patients With Chronic Illness
Status: Enrolling
Updated: 11/15/2012
Glendale Adventist Medical Center
mi
from
Glendale, CA
Click here to add this to my saved trials
Cognitive Behavioral Treatments for Depression in Chronic Illness
Cognitive Behavioral Treatments for Depression in Patients With Chronic Illness
Status: Enrolling
Updated:  11/15/2012
Duke Univ Med Ctr
mi
from
Durham, NC
Cognitive Behavioral Treatments for Depression in Chronic Illness
Cognitive Behavioral Treatments for Depression in Patients With Chronic Illness
Status: Enrolling
Updated: 11/15/2012
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Investigate Efficacy & Safety of RO4995819 vs. Placebo as Adjunct Tx in Patients w/Major Depressive Disorder
A Multi-center Randomized Double-blind Placebo-controlled Parallel-group Study to Investigate Efficacy and Safety of RO4995819 vs Placebo, as Adjunct Therapy in Patients w/Major Depressive Disorder
Status: Enrolling
Updated:  11/27/2012
Stanford University Department of Psychiatry
mi
from
Stanford, CA
Investigate Efficacy & Safety of RO4995819 vs. Placebo as Adjunct Tx in Patients w/Major Depressive Disorder
A Multi-center Randomized Double-blind Placebo-controlled Parallel-group Study to Investigate Efficacy and Safety of RO4995819 vs Placebo, as Adjunct Therapy in Patients w/Major Depressive Disorder
Status: Enrolling
Updated: 11/27/2012
Stanford University Department of Psychiatry
mi
from
Stanford, CA
Click here to add this to my saved trials
A Study in Prevention of Re-emergence of Depression Symptoms
LY2216684 Compared to Placebo as Adjunctive Therapy to SSRI in the Prevention of Symptom Re-emergence in Major Depressive Disorder
Status: Enrolling
Updated:  1/11/2013
Clinical Research Facility
mi
from
Los Angeles, CA
A Study in Prevention of Re-emergence of Depression Symptoms
LY2216684 Compared to Placebo as Adjunctive Therapy to SSRI in the Prevention of Symptom Re-emergence in Major Depressive Disorder
Status: Enrolling
Updated: 1/11/2013
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study in Prevention of Re-emergence of Depression Symptoms
LY2216684 Compared to Placebo as Adjunctive Therapy to SSRI in the Prevention of Symptom Re-emergence in Major Depressive Disorder
Status: Enrolling
Updated:  1/11/2013
Clinical Research Facility
mi
from
Miami, FL
A Study in Prevention of Re-emergence of Depression Symptoms
LY2216684 Compared to Placebo as Adjunctive Therapy to SSRI in the Prevention of Symptom Re-emergence in Major Depressive Disorder
Status: Enrolling
Updated: 1/11/2013
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
A Study in Prevention of Re-emergence of Depression Symptoms
LY2216684 Compared to Placebo as Adjunctive Therapy to SSRI in the Prevention of Symptom Re-emergence in Major Depressive Disorder
Status: Enrolling
Updated:  1/11/2013
Clinical Research Facility
mi
from
Athens, GA
A Study in Prevention of Re-emergence of Depression Symptoms
LY2216684 Compared to Placebo as Adjunctive Therapy to SSRI in the Prevention of Symptom Re-emergence in Major Depressive Disorder
Status: Enrolling
Updated: 1/11/2013
Clinical Research Facility
mi
from
Athens, GA
Click here to add this to my saved trials
A Study in Prevention of Re-emergence of Depression Symptoms
LY2216684 Compared to Placebo as Adjunctive Therapy to SSRI in the Prevention of Symptom Re-emergence in Major Depressive Disorder
Status: Enrolling
Updated:  1/11/2013
Clinical Research Facility
mi
from
Chicago, IL
A Study in Prevention of Re-emergence of Depression Symptoms
LY2216684 Compared to Placebo as Adjunctive Therapy to SSRI in the Prevention of Symptom Re-emergence in Major Depressive Disorder
Status: Enrolling
Updated: 1/11/2013
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study in Prevention of Re-emergence of Depression Symptoms
LY2216684 Compared to Placebo as Adjunctive Therapy to SSRI in the Prevention of Symptom Re-emergence in Major Depressive Disorder
Status: Enrolling
Updated:  1/11/2013
Clinical Research Facility
mi
from
Indianapolis, IN
A Study in Prevention of Re-emergence of Depression Symptoms
LY2216684 Compared to Placebo as Adjunctive Therapy to SSRI in the Prevention of Symptom Re-emergence in Major Depressive Disorder
Status: Enrolling
Updated: 1/11/2013
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study in Prevention of Re-emergence of Depression Symptoms
LY2216684 Compared to Placebo as Adjunctive Therapy to SSRI in the Prevention of Symptom Re-emergence in Major Depressive Disorder
Status: Enrolling
Updated:  1/11/2013
Clinical Research Facility
mi
from
Topeka, KA
A Study in Prevention of Re-emergence of Depression Symptoms
LY2216684 Compared to Placebo as Adjunctive Therapy to SSRI in the Prevention of Symptom Re-emergence in Major Depressive Disorder
Status: Enrolling
Updated: 1/11/2013
Clinical Research Facility
mi
from
Topeka, KA
Click here to add this to my saved trials